EPA Proposes Repeal of Stricter 2024 Rule on Medical Sterilization Gas Emissions

WASHINGTON — The U.S. Environmental Protection Agency this month announced a proposal to repeal a stringent 2024 rule that limited emissions of ethylene oxide (EtO), a gas critical for sterilizing medical equipment but also linked to cancer. The proposed reversal aims to ease regulations on approximately 90 commercial sterilization facilities nationwide to prevent significant disruptions to the U.S. medical device supply chain.

This regulatory whiplash creates significant uncertainty for businesses. For small and mid-sized companies in the medical device and healthcare sectors, navigating these shifting compliance landscapes is a major operational and financial challenge.

The new proposal would roll back key provisions of a rule finalized under the Biden administration in 2024, which was designed to cut EtO emissions by about 90%. That rule mandated that many sterilization plants install advanced pollution controls and implement continuous, around-the-clock emissions monitoring. In its new proposal, the EPA stated that some of those requirements may be too difficult and burdensome for facilities to meet.

Ethylene oxide is a cornerstone of modern healthcare. According to the Food and Drug Administration, the gas is used to sterilize roughly half of all medical devices in the United States annually—a total of about 20 billion items. These include essential equipment such as pacemakers, syringes, catheters, heart valves, stents, ventilators, and an estimated 95% of all surgical kits. For many of these devices, particularly those made from complex plastics and electronics that cannot withstand heat or radiation, EtO is the only viable and validated sterilization method currently available.

The EPA’s move follows years of debate and pressure from industry groups and lawmakers. In a September 2023 letter to the White House, leaders of the House Energy and Commerce Committee warned that the EPA’s proposed restrictions on EtO could interfere with patient safety and disrupt the nation’s healthcare system. The agency’s new rationale for repealing the 2024 rule echoes these concerns, stating that the action will “ensure a strong domestic supply chain of commercial sterilized medical equipment” that patients rely on daily.

Industry advocates have welcomed the proposed change. Scott Whitaker, president and CEO of the medical device industry group AdvaMed, said in a statement, “We appreciate the EPA’s efforts in listening to and understanding the importance of supplying safe, sterile med tech without interruption while protecting employees and communities near sterilization facilities.”

In our experience, abrupt regulatory changes like this force companies to re-evaluate their entire operational strategy. Capital that was allocated for compliance with the 2024 rule may now need to be redirected, impacting financial forecasts, risk assessments, and investor confidence. This is not just about changing equipment; it affects the fundamental business model. This is where strategic guidance becomes crucial. C&S Finance Group LLC helps businesses navigate these complex scenarios through our business process reengineering services, ensuring they can adapt efficiently without compromising their long-term stability. You can learn more at csfinancegroup.com.

However, the proposal faces strong opposition from environmental and public health advocates. EtO is classified as a carcinogen, and the 2024 rules were implemented to address cancer risks for workers in sterilization facilities and residents in surrounding communities. Environmental groups have previously filed lawsuits challenging exemptions granted to sterilization plants and are expected to contest the new proposal, arguing it prioritizes industry convenience over public safety.

The legal and jurisdictional complexities of EtO regulation are also a central part of the debate. In comments submitted during the original rulemaking process, industry groups like AdvaMed argued that the EPA was overstepping its authority under the Clean Air Act and the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). The argument posited that the EPA was encroaching on territory governed by other agencies, such as the FDA’s authority over the specifics of sterilization cycles and the Occupational Safety and Health Administration’s (OSHA) jurisdiction over worker exposure levels.

Ultimately, businesses need predictability. While this proposed rule may offer short-term relief to sterilization facilities, the potential for future legal challenges and further regulatory shifts means the uncertainty is far from over. Proactive financial risk management is essential for any company operating in this volatile environment.

The EPA’s proposal is now subject to a public comment period. The final shape of the regulation will depend on the feedback received from industry stakeholders, public health organizations, and environmental groups, as well as the outcome of any ensuing legal battles, leaving the future of medical device sterilization in a continued state of flux.